All key study objectives regarding pharmacokinetic (PK), pharmacodynamic (PD), safety, and clinical activity were met. Presented findings included: No dose-limiting toxicities or significant off ...

Objective response (ELN 2017 ... Following completion of the dose escalation phase in relapsed/refractory acute leukemia patients with FLT3 mutations, Biomea plans to conclude its internal ...

Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. Additionally, the Company is ...

As previously announced, the ALPINE trial met its primary endpoint, with BRUKINSA demonstrating non-inferiority in objective response rate (ORR ... with relapsed or refractory chronic lymphocytic ...